Our technology is focused on delivering differentiated and novel dosage forms to our business associates, ensuring premium product leadership and providing unique and enhanced health solutions to patients—affordably.
Therapy-Agnostic
Multiple Technology Platforms:
1. Pellets with different release patterns :
We specialize in the development and manufacture of pellets with diverse release profiles, including immediate, delayed, controlled, sustained, targeted release, etc. These modified-release pellets enhance patient convenience by reducing dosage frequency while minimizing side effects.
2. Taste Masking :
We have mastered the art of masking the taste of bitter molecules without compromising their dissolution profile, bioavailability, or shelf life. Our taste-masked dry powders, dry syrups, and orally disintegrating films are widely accepted by patients, significantly improving compliance.
3. Directly Compressible (DC) Granules :
Directly compressible granules simplify tablet production, as they are one step away from being converted into the final product. Utilizing state-of-the-art technology, we manufacture directly compressible granules with modified-release profiles.
Our high-tech products empower PFI customers to address unmet medical needs in their markets, ultimately benefiting the patient community.
4. Oral Thin Films (OTF) :
We are among the few companies globally with in-house technology for manufacturing oral thin films.
A) Thinoral® Technology :
Our patented Thinoral® technology produces instantly wettable, rapidly dissolving, non-sticky, non-tacky, and non-curving films. Key features include:
- High drug loading of 50-60 mg per film.
- Uniform thinness providing a large surface area for dissolution.
- Enhanced solubility for poorly soluble drugs.
- Suitability for thermolabile drug delivery.
B) MucoStrip® Technology :
Mucostrip® is a distinctive dosage form designed to be placed on the tongue, eliminating the need for water during administration.
C) Sublingual Technology :
Sublingual drug administration involves placing the medication under the tongue for rapid absorption.
D) Bilayer Oral Thin Film Technology :
Bilayer-OTF technology reduces the pill burden for patients by allowing the administration of two or more active pharmaceutical ingredients (APIs) in a single fixed-dose combination (FDC).
5. New Innovative Products (NIP) :
We are driving innovation with our New Innovative Products (NIP), featuring complex generics developed through in-house proprietary technology.
A) Micro-Emulsion Coating
Technology (MECT) :
Used for the solubilization of oil-soluble drugs and liquids in the oil phase, followed by micro-emulsification with an aqueous phase containing polymers to coat the substrate.
B) Pellet Cold Forming Technology
(PCFT) :
Used for heat-sensitive materials that either lose their potency or transform into another form when processed at normal temperatures.
C) Rapid Gelation Drug Release
Technology (RGDRT) :
Used for drug release in pseudo-zero kinetics and serves as an alternative to OROS® technology.
D) Matrix Pore Forming Tablet
Technology (MAPOTAB) :
Matrix Pore Forming Tablet Technology (MAPOTAB) is used for the controlled release of drugs through pores into an aqueous medium.